Attenuating the EGFR-ERK-SOX9 axis promotes liver progenitor cell‐mediated liver regeneration in zebrafish by So, Juhoon et al.
1 
 
Supporting Information 
Supporting Methods 
Genotyping of egfra and sox9b mutants  
For egfra genotyping, genomic DNA was amplified with a forward (5’-ACTTCCAGGATGAAGGGACA-3’) 
and a reverse (5’-CTTACGTGGGCATGTCTTGA-3’) primer pair; the wild-type and mutant allele displayed 
137-bp and 153-bp PCR products, respectively. For sox9b genotyping, genomic DNA was amplified with 
either wild-type allele- (5’-AGACCAGTCGTAGCCCTT-3’) or mutant allele-specific (5’-
AGACCAGTCGTAGCCCTA-3’) reverse primer and a common forward primer (5’-
TGAGTGTGTCCGGAGCTCCGA-3’). 
 
Generation of the Tg(fabp10a:rtTA,TRE:Venus-KRAS) line 
Gateway cloning (Thermo fisher Scientific) was used to make the fabp10a:rtTA-pA,TRE:CFP-pA construct 
with three entry clones (p5E_the fabp10a promoter, pME_rtTA-pA, and p3E_TRE:CFP-pA) and a 
destination vector having two I-SceI sites. The Venus-KRAS-pA construct was made by fusing Venus to the 
human KRASG12V gene. To make the final fabp10a:rtTA-pA,TRE:Venus-KRAS-pA construct, the CFP-pA 
region in the fabp10a:rtTA-pA,TRE:CFP-pA construct was replaced with Venus-KRAS-pA by regular 
cloning. One nl of the solution containing the final construct (20 ng/ul) and I-SceI meganuclease was 
microinjected into one-cell stage embryos as previously described (1). The injected embryos/larvae were 
treated with 10 ug/ml doxycycline from 3 to 4 dpf and larvae expressing Venus in the liver were selected at 
4 or 5 dpf and raised to adulthood. Embryos from these adult fish were treated with doxycycline to identify 
founder fish with germline integration. F1 larvae, which expressed strong Venus expression in the entire 
liver, were selected and raised to establish the line.   
 
In situ hybridization and immunostaining 
Whole-mount (2) and section (3) in situ hybridization was performed as previously described. cDNA from 3- 
or 5-dpf larvae was used as a template for PCR to amplify genes-of-interest; PCR products were used to 
make in situ probes. The primers used for the probe synthesis are listed in Table S2. Immunostaining was 
performed as previously described (4), using the following antibodies: mouse anti-Bhmt (1:500; gift from 
Jinrong Peng at Zhejiang University), rabbit anti-Tp53 (1:200; gift from Jinrong Peng), mouse anti-Alcama 
(1:20; ZIRC, zn-5), mouse anti-Anxa4 (1:300; Abcam, ab71286), rabbit anti-Abcb11 (1:1000; Kamiya 
Biomedical, PC-064), rabbit anti-DsRed (1:200; Clontech, 632496), rabbit anti-Collagen I (1:100; Abcam, 
ab34710), rabbit anti-pH2AX (1:100; GeneTex, GTX127342), mouse anti-pErk1/2 (1:100; Sigma, M8159), 
rabbit anti-Sox9b (1:50; gift from Mizuki Azuma at the University of Kansas), and Alexa Fluor 488-, 568-, 
and 647-conjugated secondary antibodies (1:500; Thermo Fisher Scientific). For section, larvae were fixed 
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with 4% paraformaldehyde/PBS, embedded in Tissue Freezing Medium (Ted Fella), and cryo-sectioned to 
12-µm thickness.  
 
qPCR 
Total RNA was extracted from 30-40 dissected livers for each condition using the RNeasy Micro Kit 
(Qiagen); cDNA was synthesized from the RNA using the SuperScript® III First-Strand Synthesis 
SuperMix (Thermo Fisher Scientific) according to the kit protocols. qPCR was performed as previously 
described (5), using the QuantStudio 12K Flex machine (Applied Biosystems) with the iTaqTM Universal 
SYBR® Green Supermix (Bio-Rad). eef1a1l1 was used for normalization as previously described (6). 
At least three independent experiments were performed. The primers used for qPCR are listed in Table 
S3. 
 
Cre/loxP-mediated lineage tracing 
Tg(Tp1:CreERT2);Tg(fabp10a:pt-β-catenin), Tg(fabp10a:CreERT2);Tg(fabp10a:pt-β-catenin), 
Tg(Tp1:CreERT2);Tg(fabp10a:UHRF1-GFP), and Tg(fabp10a:CreERT2);Tg(fabp10a:UHRF1-GFP) fish 
were crossed to the Cre reporter line, Tg(ubb:loxP-GFP-loxP-mCherry). Larvae from the crosses were 
treated with 10 μM 4-OHT (Sigma) from 60 to 96 hours post-fertilization for 36 hours. The larvae were 
harvested at 15 or 30 dpf for Tg(fabp10a:pt-β-catenin) fish and at 20 dpf for Tg(fabp10a:UHRF1-GFP) fish 
and processed for immunostaining to reveal lineage-traced mCherry+ cells as previously described (7). 
 
Cre/loxP-mediated overexpression of Sox9b and dnSox9b 
Tg(fabp10a:CreERT2);Tg(fabp10a:pt-β-catenin) larvae containing the ubb:loxP-CFP-loxP-sox9b-2A-
mCherry or ubb:loxP-CFP-loxP-dnsox9b-2A-mCherry transgene were treated with 10 µM 4-OHT from 11 to 
12 dpf for 24 hours. The larvae were harvested at 15 dpf for dnSox9b overexpression and 20 dpf for Sox9b 
overexpression and processed for immunostaining. 
 
Tetracycline-inducible overexpression of KRAS 
Tg(fabp10a:rtTA,TRE:KRAS);Tg(fabp10a:pt-β-catenin) larvae were treated with 10 µg/ml doxycycline 
(Sigma) from 12 to 14 dpf. The larvae were harvested at 14 dpf and processed for immunostaining. 
 
Senescence-associated β-galactosidase staining 
Senescence-associated β-galactosidase staining was performed as described in the protocol of the 
Senescence β-galactosidase Staining Kit (Cell Signaling). Briefly, larvae were fixed with fixative solution in 
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the kit overnight. One ml of the β-galactosidase staining solution was added into each tube and the larvae 
were incubated at 37 °C overnight.       
 
TUNEL assay 
TUNEL labeling was performed as described in the protocol of the In Situ Cell Death Detection Kit, TMR red 
(Roche). Sectioned samples on slides were treated with 200 ul of TUNEL reaction mixture and incubated at 
37 ºC for 1 hour.   
 
BODIPY C5 staining 
BODIPY C5 assay was performed by treating larvae with 0.5 µM BODIPY C5 (Thermo Fisher Scientific) for 
2 hours, as previously described (8). BODIPY C5-treated larvae were briefly rinsed, anesthetized with 
0.016% tricaine/egg water, and then mounted in 1% low-melting agarose for live confocal imaging. 
 
H&E staining 
Liver tissue samples were fixed with Dietrich's fixative (9) (3.7% formaldehyde, 2% glacial acetic acid, 30% 
ethanol) at room temperature for 24 hours and processed for paraffin embedding. Paraffin block was 
prepared as previously described (10). Samples were cut into 5-µm sections, deparaffinized and stained 
with hematoxylin and eosin (Thermo Fisher Scientific), followed by dehydration to xylene and application of 
a coverslip with Cytoseal™ XYL (Thermo Fisher Scientific). Images were taken using a Zeiss Axioskop 40 
bright-field microscope. 
 
Heat-shock condition 
Tg(hsp70l:dnHRAS) larvae were heat-shocked twice at 13 and 14 dpf by transferring them into system 
water pre-warmed to 38 °C and keeping them at this temperature only for 30 minutes as previously 
described (11).  
 
Survival assays 
For Tg(fabp10a:pt-β-catenin) survival assay, each 30 Tg(fabp10a:pt-β-catenin) larvae were first treated with 
DMSO or AG1478 from 13 to 15 dpf and then with 10 µM 4-OHT from 15 to 16 dpf. At 16 dpf, the number of 
survived larvae was counted. For Tg(fabp10a:UHRF1-GFP) survival assay, each 100 Tg(fabp10a:UHRF1-
GFP) larvae were treated with DMSO or AG1478 from 9 to 10 dpf. At 20 dpf, the number of survived larvae 
was counted. Three independent experiments were performed. 
 
Hepatocyte ablation using the Tg(fabp10a:CFP-NTR) line 
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Tg(fabp10a:CFP-NTR) fish express cyan fluorescent protein (CFP) and nitroreductase (NTR) fusion 
proteins under the hepatocyte-specific fabp10a promoter. NTR converts the nontoxic prodrug, 
metronidazole (Mtz), into a cytotoxic drug, thereby ablating only NTR-expressing cells (12, 13). Hepatocyte 
ablation was performed by treating Tg(fabp10a:CFP-NTR) larvae with 10 mM Mtz in egg water 
supplemented with 0.2% DMSO and 0.2 mM 1-phenyl-2-thiourea from 3.5 to 5 dpf for 36 hours, as 
previously described (7). The larvae were treated with 2 µM AG1478 from A20h (ablation 20 hour) to R6h 
(regeneration 6 hour) and harvested at R6h for subsequent whole-mount in situ hybridization.     
 
Quantification of Bhmt+ liver area  
Confocal images of anti-Bhmt immunostaining and fabp10a:CFP intrinsic fluorescence were used to 
quantify Bhmt+ liver area. Both Bhmt+ and fabp10a:CFP+ areas in the liver were calculated by ImageJ and 
the former area was divided by the latter.  
 
Image acquisition, processing, and statistical analysis 
Zeiss LSM700 confocal, Axioskop 40 bright-field, and Leica MZ16 microscopes were used to obtain image 
data. Confocal stacks were analyzed using the Zen 2009 software. All figures, labels, arrows, scale bars, 
and outlines were assembled or drawn using the Adobe Illustrator software. Statistical analyses were 
performed using the GraphPad Prism software. Differences among groups were tested by unpaired 
Student’s t-tests or one-way ANOVA. Differences were considered statistically significant when P < 0.05 (*P 
< 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).  
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Supporting figures 
 
 
Figure S1. Hepatocyte-specific overexpression of pt-β-catenin induces hepatocyte damage, 
inflammation and fibrosis in the liver. (A) Quantification of the percentage of p53-positive cells among 
fabp10a:CFP+ hepatocytes in the liver of Tg(fabp10a:pt-β-catenin) and control larvae at 7 dpf. (B, C) 
Quantification of the percentage of pH2AX+ (B) or TUNEL+ (C) cells among fabp10a:CFP+ hepatocytes in 
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the liver of Tg(fabp10a:pt-β-catenin) and control larvae at 10 dpf. (D) Confocal images showing the hepatic 
expression of fabp10a:CFP, Tp1:H2B-mCherry, and mpeg1:Dendra2 (macrophages) at 5, 7, 10, 15, 20, and 
30 dpf. Arrows point to macrophages. (E) Confocal images showing the hepatic expression of fabp10a:CFP, 
Tp1:H2B-mCherry, and hand2:EGFP (HSCs) at 15 and 30 dpf. (F) Confocal images showing the hepatic 
expression of fabp10a:CFP, Anxa4 (BECs/LPCs), and Collagen I (fibrosis) at 20 and 30 dpf. Arrowheads 
point to Collagen I-positive cells. (G) Confocal images showing the hepatic expression of fabp10a:GFP and 
acta2:mCherry (fibrosis) at 20 dpf. Scale bars, 50 µm. Data are presented as mean ± s.d. **P<0.01, 
***P<0.001; statistical significance was calculated using an unpaired two-tailed t-test.   
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Figure S2. The process of liver recovery in Tg(fabp10a:pt-β-catenin) zebrafish. (A) Confocal images 
showing the hepatic expression of Anxa4 or Alcama (LPCs/BECs) and fabp10a:CFP at 15 dpf. (B) qPCR 
data showing the relative expression levels of epcam, her9, krt18, and sox9b between Tg(fabp10a:pt-β-
catenin) and control livers at 5, 10, 15, 20, and 30 dpf. Data are presented as mean ± s.e.m. (C) Confocal 
images showing BODIPY C5 staining in the liver (dotted lines) at 5, 10, 20, and 30 dpf. Arrows point to 
labeled bile ductules; an asterisk indicates the region without bile flow. (D) Section in situ hybridization 
images showing the hepatic expression of pt-β-catenin (Xla.ctnnb1) in control and Tg(fabp10a:pt-β-catenin) 
larvae at 10, 15, and 30 dpf. The asterisk denotes the region without pt-β-catenin expression. (E) Confocal 
images showing the expression of WRE:d2GFP (Wnt/β-catenin activity) and Bhmt (hepatocytes) in the liver 
8 
 
at 10, 15, and 30 dpf. The asterisk denotes Bhmt-positive but WRE:d2GFP-negative region. Numbers in the 
lower right corner indicate the proportion of larvae exhibiting the phenotype shown. Scale bars, 50 µm. 
 
 
 
 
 
Figure S3. The process of liver regeneration and recovery in Tg(fabp10a:UHRF1-GFP) fish. (A) 
Confocal images showing the hepatic expression of fabp10a:UHRF1-GFP, Tp1:H2B-mCherry, and Bhmt at 
5, 7, 10, 15, and 20 dpf. Quantification of Bhmt-positive area in Tg(fabp10a:pt-β-catenin) livers is shown. 
Data are presented as mean ± s.d. (B) Confocal images showing the hepatic expression of 
fabp10a:UHRF1-GFP, Tp1:H2B-mCherry, and Anxa4 at 5, 7, 10, 15, and 20 dpf. Arrows point to LPCs. (C) 
Confocal images showing the hepatic expression of fabp10a:UHRF1-GFP, Bhmt, and acta2:mCherry 
(fibrosis) at 10 dpf. Arrowheads point to acta2:mCherry+ cells. Dotted lines outline livers. Scale bars, 50 µm.  
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Figure S4. Lineage tracing in Tg(fabp10a:pt-β-catenin) and Tg(fabp10a:UHRF1-GFP) zebrafish. (A, B) 
Labeling efficacy of the fabp10a:CreERT2 and Tp1:CreERT2 lines in the Tg(fabp10a:pt-β-catenin) 
background. Confocal images showing the hepatic expression of mCherry (lineage-traced cells) and Bhmt 
(hepatocytes, A) or Alcama (BECs, B) in Tg(fabp10a:pt-β-catenin) larvae at 5 dpf. Arrows point to 
mCherry/Alcama double-positive hepatocytes. (C, D) Hepatocyte-labeling efficacy of the fabp10a:CreERT2 
and Tp1:CreERT2 lines in the control background. Confocal images showing the hepatic expression of 
mCherry (lineage-traced cells) and Bhmt (hepatocytes) in control larvae at 30 dpf. (E, F) Confocal images 
showing the expression of mCherry (lineage-traced cells) and Anxa4 (E) or Alcama (F) in Tg(fabp10a:pt-β-
catenin) livers at 15 dpf. Arrows point to mCherry/Anxa4 double-positive cells; arrowheads point to 
mCherry/Alcama double-positive cells. (G, H) Confocal images showing the expression of mCherry 
(lineage-traced cells) and Bhmt (hepatocytes) in Tg(fabp10a:UHRF1-GFP) livers at 20 dpf. Arrows point to 
mCherry/Bhmt double-positive hepatocytes. For Cre-mediated cell labeling, embryos/larvae were treated 
with 4-OHT from 2.5 to 4 dpf. Dotted lines outline livers. Data are presented as mean ± s.d. Scale bars, 50 
µm. 
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Figure S5. EGFR inhibition promotes liver recovery. (A) Section in situ hybridization images showing the 
expression of hepatocyte markers (cyp2ad2 and serpina1) in control and Tg(fabp10a:pt-β-catenin) larvae at 
15 dpf. (B) Confocal images showing the hepatic expression of Abcb11 (bile canaliculus, arrows) and 
fabp10a:CFP in 15-dpf Tg(fabp10a:pt-β-catenin) larvae (C) Confocal projection images showing BODIPY 
C5 labeling in Tg(fabp10a:pt-β-catenin) livers at 15 dpf. Arrows point to labeled bile ductules. (D) Scheme 
illustrates AG1478 and 4-OHT treatments and analysis stage for survival assay. Quantification shows the 
survival rate of Tg(fabp10a:pt-β-catenin) larvae. 30 larvae were used for each condition. (E) Confocal 
images showing the hepatic expression of acta2:mCherry (arrows) in 15-dpf Tg(fabp10a:pt-β-catenin) 
larvae. qPCR data show the relative expression levels of fibrosis markers (acta2 and col1a1a) between 
DMSO- and AG1478-treated Tg(fabp10a:pt-β-catenin) livers. Scale bars, 50 µm. Dotted lines outline livers. 
Data are presented as mean ± s.d. *P<0.05, ***P<0.001; statistical significance was calculated using an 
unpaired two-tailed t-test. 
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Figure S6. EGFR inhibition promotes LPC-to-hepatocyte differentiation in two additional liver injury 
models, Tg(fabp10a:UHRF1-GFP) and Tg(fabp10a:CFP-NTR). (A) Scheme illustrates AG1478 treatment 
and analysis stage. Confocal images show the hepatic expression of Bhmt, Tp1:H2B-mCherry, and 
fabp10a:UHRF1-GFP in 10-dpf Tg(fabp10a:UHRF1-GFP) larvae. Quantification of the percentage of Bhmt-
positive liver area is shown. Arrows point to Bhmt+ hepatocytes. (B) Scheme illustrates AG1478 treatment 
and analysis stage. Quantification of the survival rate of Tg(fabp10a:UHRF1-GFP) larvae at 20 dpf is 
shown. 100 larvae were used for each condition. (C) Scheme illustrates the periods of metronidazole (Mtz; 
hepatocyte ablation) and AG1478 treatments and analysis stage. Whole-mount in situ hybridization images 
show gc expression in regenerating Tg(fabp10a:CFP-NTR) livers at R6h (Regeneration 6 hours). (D) 
Scheme illustrates the period of Mtz treatment and analysis stage. Whole-mount in situ hybridization images 
show gc expression in regenerating Tg(fabp10a:CFP-NTR) livers at R6h in the egfra mutant background. 
Based on the level of hepatic gc expression, larvae were divided into three groups: no, weak, and strong. 
Numbers in the graph indicate the number of larvae in each group. An arrow points to the liver. Data are 
presented as mean ± s.d. (A, B, D) or ± s.e.m. (C). *P<0.05; statistical significance was calculated using an 
unpaired two-tailed t-test.  
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Supporting tables 
Table S1. Transgenic and mutant zebrafish lines used in this study 
Names  Official names (ZFIN database) Allele # 
Tg(fabp10a:pt-β-catenin) Tg(fabp10a:Xla.Ctnnb1,cryaa:Venus) s704 
Tg(fabp10a:UHRF1-GFP) Tg(fabp10a:Hsa.UHRF1-EGFP) mss1a 
Tg(mpeg1:Dendra2) Tg(mpeg1.1:Dendra2) uwm12 
Tg(hand2:EGFP) TgBAC(hand2:EGFP) pd24 
Tg(acta2:mCherry) Tg2(acta2:mCherry) uto5 
Tg(fabp10a:GFP) Tg(-2.8fabp10a:EGFP) as3 
Tg(fabp10a:CFP) Tg(fabp10a:CFP-NTR) s931 
Tg(WRE:d2GFP) Tg(OTM:d2EGFP)  kyu1 
Tg(Tp1:VenusPEST) Tg(EPV.Tp1-Mmu.Hbb:Venus-Mmu.Odc1) s940 
Tg(Tp1:H2B-mCherry) Tg(EPV.Tp1-Mmu.Hbb:hist2h2l-mCherry) s939 
Tg(fabp10a:CreERT2) Tg(fabp10a:Cre-ERT2,cryaa:ECFP) pt602 
Tg(Tp1:CreERT2)  Tg(EPV.Tp1-Mmu.Hbb:Cre-ERT2,cryaa:mCherry) s959 
Tg(ubb:loxP-GFP-loxP-mCherry) Tg(-3.5ubb:loxP-EGFP-loxP-mCherry) cz1701 
Tg(hsp70l:dnHRAS) Tg(hsp70l:dnHRAS,cryaa:EGFP) pd7 
Tg(fabp10a:rtTA,TRE:Venus-KRAS) Tg(fabp10a:rtTA,TRE:Venus-KRASG12V) pt618 
Tg(ubb:loxP-CFP-loxP-sox9b-2A-
mCherry) Tg(ubb:loxP-eCFP-loxP-sox9b-2A-mCherry) jh47 
Tg(ubb:loxP-CFP-loxP-dnsox9b-2A-
mCherry) Tg(ubb:loxP-eCFP-loxP-trsox9b-2A-mCherry) jh48 
egfra egfra ct870 
sox9b sox9b fh313 
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Table S2. Sequences of primers used for in situ probe synthesis 
Gene Primer Nucleotide sequence (5' to 3') 
tp53 forward AAGAACAGCCTCAGCCATCC 
tp53 reverse TAATACGACTCACTATAGGGTCCATTCAGCACCAAGCTGT 
cdkn1a forward CAAGCGGATCCTACGTTCAC 
cdkn1a reverse TAATACGACTCACTATAGGGCTGGGGTTTTCTCCACTTCA 
ces2 forward GGAATATTAGGATACTTCAGCACAG 
ces2 reverse TAATACGACTCACTATAGGGAAAATCTGGGGGAGCATCCA 
ces3 forward GGCTTCAGAAGCCAATGGAATC 
ces3 reverse TAATACGACTCACTATAGGGTCAGGCTGTATGAAGTGCAGC 
tdo2a forward AACCAGCCTCGGAGAGGAAG 
tdo2a reverse TAATACGACTCACTATAGGGATCTTCTCCTCATTCCTCCATC 
cyp2ad2 forward CACCACCATGATCCTGCACCTG 
cyp2ad2 reverse TAATACGACTCACTATAGGGAACCTCCTATGTGACCGCCAG 
serpina1 forward CATGTTGGGTCACAGTCAGG 
serpina1 reverse TAATACGACTCACTATAGGGGCCTTTGTAGGGCACCATCAT 
egfra forward TCCCGCACACAACTGCTGCA 
egfra reverse TAATACGACTCACTATAGGGATCTGCTAGTGCACCTCCAG 
Xla.ctnnb1 forward GAAACTGCTTAATGACGAGGACC 
Xla.ctnnb1 reverse TAATACGACTCACTATAGGGCACCAGCTTCAACTATAGCAGGC 
Underlined are T7 primer sequences. 
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Table S3. Sequences of primers used for qPCR 
Gene Primer Nucleotide sequence (5' to 3') 
eef1a1l1 forward CTGGAGGCCAGCTCAAACAT 
eef1a1l1 reverse ATCAAGAAGAGTAGTACCGCTAGCATTAC 
tp53 forward CTCTCCCACCAACATCCACT 
tp53 reverse GATTGCCCTCCACTCTTATCA 
cdkn1a forward CCGCATGAAGTGGAGAAAAC 
cdkn1a reverse ACGCTTCTTGGCTTGGTAGA 
mdm2 forward CCTCCTCTTCCTCGACACTG 
mdm2 reverse GGGTCTCTTCCTGACTGCTG 
bhmt forward CTGATCGCTGAGTACTTTG 
bhmt reverse CAATGAAGCCCTGGCAGC 
ces2 forward GGAATATTAGGATACTTCAGCACAG 
ces2 reverse CTGTAAAGCTGCGATCTGG 
ces3 forward TGAAAGTTACAGGAACACTCAC 
ces3 reverse TACGAACAAAGTTAGCCCAG 
cyp2ad2 forward CACTCAGAATGATAGCTTCGT 
cyp2ad2 reverse CTCATTGTTAAACCGATTCCC 
cyp7a1a forward CCTACCATGCTGTCATCCGTC 
cyp7a1a reverse TCTCATGACCAAATGCCTTCGC 
gc forward CAAGCATGGGTTTCTTGGG 
gc reverse AACCTCCTCTGTCAGTTTCTG 
serpina1 forward CATGTTGGGTCACAGTCAGG 
serpina1 reverse CGATTTCAGGCTTGGAGAA 
tdo2a forward GATGATTGGCAGTAAAGACGG 
tdo2a reverse ACCTTGTAGCGATCACTGAC 
epcam forward CTTGTTTGTTGTGGCATTGG 
epcam reverse TTGACGCACCAGCATACTTC 
krt18 forward CGTCGCCGCTTACAAGAAAGAAC 
krt18 reverse ATGTGTCTCCGCAGATGTCGTC 
sox9b forward CAGAAACACCCGACTCCAG 
sox9b reverse CACACCGGCAGATCTGTTT 
her9 forward AATGCCAGCGAGCATAGAAAGTC 
her9 reverse TGCCCAAGGCTCTCGTTGATTC 
acta2 forward CCGTGATCTCACTGACTACC 
acta2 reverse ACGATTTCTCTTTCAGCAGTG 
col1a1a forward GGTAAAGATGGCATTCGTGG 
col1a1a reverse AGATTCTCCCTTGTCACCAG 
egfra forward GCCAGAGAATGACGAAAGTG 
egfra reverse CATTACAGCAGTCAATGGGTC 
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